Literature DB >> 27492426

Update on the Management of Pancreatic Cancer in Older Adults.

Shin Yin Lee1, Moussa Sissoko2, Kevan L Hartshorn3.   

Abstract

Pancreatic cancer is more common in older adults, who are underrepresented in clinical trials and frequently under treated. Chronological age alone should not deter clinicians from offering treatment to geriatric patients, as they are a heterogeneous population. Geriatric assessment, frailty assessment tools, and toxicity risk scores help clinicians select appropriate patients for therapy. For resectable disease, surgery can be safe but should be done at a high-volume center. Adjuvant therapy is important; though there remains controversy on the role of radiation, chemotherapy is well studied and efficacious. In locally advanced unresectable disease, chemoradiation or chemotherapy alone is an option. Neoadjuvant therapy improves the chances of resectability in borderline resectable disease. Chemotherapy extends survival in metastatic disease, but treatment goals and risk-benefit ratios have to be clarified. Adequate symptom management and supportive care are important. There are now many new treatment strategies and novel therapies for this disease.

Entities:  

Keywords:  Chemoradiation; Chemotherapy; Comprehensive geriatric assessment; Frailty scores; Geriatric oncology; Novel therapies; Older adults; Pancreatic adenocarcinoma; Radiation; Surgery; Symptom management; Toxicity scores; Update

Mesh:

Year:  2016        PMID: 27492426     DOI: 10.1007/s11912-016-0547-4

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  87 in total

1.  One thousand consecutive pancreaticoduodenectomies.

Authors:  John L Cameron; Taylor S Riall; JoAnn Coleman; Kenneth A Belcher
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

2.  Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.

Authors:  Arti Hurria; Kayo Togawa; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Smita Bhatia; Vani Katheria; Shira Klapper; Kurt Hansen; Rupal Ramani; Mark Lachs; F Lennie Wong; William P Tew
Journal:  J Clin Oncol       Date:  2011-08-01       Impact factor: 44.544

3.  Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?

Authors:  Kathleen K Christians; Susan Tsai; Anna Mahmoud; Paul Ritch; James P Thomas; Lauren Wiebe; Tracy Kelly; Beth Erickson; Huamin Wang; Douglas B Evans; Ben George
Journal:  Oncologist       Date:  2014-02-25

4.  Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

Authors:  Dung T Le; Andrea Wang-Gillam; Vincent Picozzi; Tim F Greten; Todd Crocenzi; Gregory Springett; Michael Morse; Herbert Zeh; Deirdre Cohen; Robert L Fine; Beth Onners; Jennifer N Uram; Daniel A Laheru; Eric R Lutz; Sara Solt; Aimee Luck Murphy; Justin Skoble; Ed Lemmens; John Grous; Thomas Dubensky; Dirk G Brockstedt; Elizabeth M Jaffee
Journal:  J Clin Oncol       Date:  2015-01-12       Impact factor: 44.544

5.  Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010.

Authors:  Chenjie Zeng; Wanqing Wen; Alicia K Morgans; William Pao; Xiao-Ou Shu; Wei Zheng
Journal:  JAMA Oncol       Date:  2015-04       Impact factor: 31.777

6.  Pancreatectomy for adenocarcinoma in elderly patients: postoperative outcomes and long term results: a study of the French Surgical Association.

Authors:  O Turrini; F Paye; P Bachellier; A Sauvanet; A Sa Cunha; Y P Le Treut; M Adham; J Y Mabrut; L Chiche; J R Delpero
Journal:  Eur J Surg Oncol       Date:  2012-09-19       Impact factor: 4.424

7.  Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer.

Authors:  Jonathan M Wyse; Marco Carone; Sarto C Paquin; Mariana Usatii; Anand V Sahai
Journal:  J Clin Oncol       Date:  2011-08-15       Impact factor: 44.544

Review 8.  What is the effect of age on pancreatic resection?

Authors:  Taylor S Riall
Journal:  Adv Surg       Date:  2009

9.  Participation in cancer clinical trials: race-, sex-, and age-based disparities.

Authors:  Vivek H Murthy; Harlan M Krumholz; Cary P Gross
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

10.  SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience.

Authors:  Angelo Tozzi; Tiziana Comito; Filippo Alongi; Pierina Navarria; Cristina Iftode; Pietro Mancosu; Giacomo Reggiori; Elena Clerici; Lorenza Rimassa; Alessandro Zerbi; Antonella Fogliata; Luca Cozzi; Stefano Tomatis; Marta Scorsetti
Journal:  Radiat Oncol       Date:  2013-06-21       Impact factor: 3.481

View more
  2 in total

Review 1.  Nanotechnologies in Pancreatic Cancer Therapy.

Authors:  Ayesha Manzur; Adeolu Oluwasanmi; Darren Moss; Anthony Curtis; Clare Hoskins
Journal:  Pharmaceutics       Date:  2017-09-25       Impact factor: 6.321

2.  Can Elderly Patients With Pancreatic Cancer Gain Survival Advantages Through More Radical Surgeries? A SEER-Based Analysis.

Authors:  Danna Xie; Baolin Qian; Jing Yang; Xinya Peng; Yinghua Li; Teng Hu; Simin Lu; Xiaojing Chen; Yunwei Han
Journal:  Front Oncol       Date:  2020-10-29       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.